WHO vaccine-preventable diseases: monitoring system. 2014 global summary

Last updated 15-Jul-2014 (Data received as of 8-Jul-2014)
Next overall update Fall 2014
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 18'0601 Infant (under 12 months) mortality rate: 32
GDP / capita (US$): 27'3441 Child (under 5 years) mortality rate: 42

Population data in thousands3

  2013  2012  2011  2010  2009  2000  1990  1980 
Total population 10'702  10'660  10'611  10'554  10'486  10'250  10'326  10'313 
Births 118  118  118  117  115  88  128  162 
Surviving infants 118  118  117  116  115  87  127  159 
Pop. less than 5 years 601  600  594  578  565  441  646  898 
Pop. less than 15 years 1'591  1'557  1'526  1'498  1'485  1'686  2'221  2'426 
Female 15-49 years 2'523  2'534  2'541  2'546  2'544  2'588  2'580  2'423 

Number of reported case

(Click for retrospective incidence data for Czech Republic (the))
Diphtheria
Japanese encephalitis
Measles 15  22  17  2'420 
Mumps 1'553  3'902  2'885  1'068  357  120 
Pertussis 1'233  738  324  662  956  187  48 
Polio*
Rubella 27  743 
Rubella (CRS)
Tetanus (neonatal)
Tetanus (total)
Yellow fever
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV);"
"it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Czech Republic (the))
Vaccine year result method % card seen                                                
BCG          99 
DTP1         
DTP3          99  99  99  98 
HepB_BD         
HepB3          99  99  99  99  99 
Hib3          99  99  99  99 
JapEnc         
MCV         
MCV2          99  98  98  98  98  97 
PCV1         
PCV3         
Pol3          99  99  99  99  99  97 
Rota1         
Rota_last         
Rubella1          99  98  98  98 
TT2plus         
PAB         
VAD1         
YFV         
  ° indicates that more than 1 survey occurred that year

  Next update: July 2015

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Czech Republic (the))
BCG 98  98 
DTP1 99  99  99  99  99  99 
DTP3 99  99  99  99  99  98 
HepB3 99  99  99  99  99 
HepB_BD
Hib3 99  99  99  99  99 
MCV 99  98  98  98  98  97 
MCV2
PCV3
Pol3 99  99  99  99  99  98 
Rota_last

Number of districts in the country 86  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 99
From 80 to 89% 1
From 50 to 79% 0
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
 

Immunization Schedule (2013 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
DTaP 5 years; Yes
DTaPHibHepIPV 9, 13, 17 weeks; 18 months; Yes
DTaPIPV 10 years; Yes
HPV 13 years;
HepB 12 years (x3); Yes
Influenza > 65 years; Yes
MMR 15, 21 months; Yes
Pneumo_conj 4, 5, 6, 11-18 months; Yes
Pneumo_ps Yes risk groups
TT 25 years; Yes

Immunizaton indicators

Indicator Expected answer 2013  2012  2011  2010  2009  2008  2007 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number 3 years  3 years  3 years  3years  3 years  3 years  3 years 
Nº of districts with microplans that include activities to raise immunization coverage number 86  86  86  86  86  86  86 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes       

System performance

Total Nº districts in country number 86  86  86  86  86  86  86 
Nº districts with DTP3 coverage >=80% number 86  86  86  86  86 
% of districts with DTP3 coverage >=80% From 0 to 100% 100  100  100  100  100 
Nº districts with measles (MCV1) coverage >=95% number 84  86    79       
% of districts with MCV1 coverage >=95% From 0 to 100% 98  100    92       

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND   No    No       
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

Estimated percentage of routine vaccines funded by Government From 0 to 100%         100  100 

Sources

Unless otherwise specified, data provided by Member States through WHO-UNICEF Joint Reporting Form and WHO Regional offices.
 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.